NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2021 - 2026)

NewAmsterdam Pharma has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $732.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $732.6 million, down 10.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 20.81% YoY), and the FY2025 annual result was $769.3 million, down 11.03% from the prior year.
• Liabilities and Shareholders Equity came in at $732.6 million for Q1 2026 at NewAmsterdam Pharma, down from $769.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $864.6 million in Q4 2024 to a low of $347.1 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $637.5 million (2022), against an average of $630.3 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 693.03% in 2022 and slumped 36.0% in 2023, its largest moves.
• NewAmsterdam Pharma's Liabilities and Shareholders Equity stood at $542.3 million in 2022, then plunged by 36.0% to $347.1 million in 2023, then soared by 149.1% to $864.6 million in 2024, then fell by 11.03% to $769.3 million in 2025, then slipped by 4.76% to $732.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $732.6 million (Q1 2026), $769.3 million (Q4 2025), and $786.4 million (Q3 2025), per Business Quant data.